Clinical Trials Browser

INDUSTRY × Uveal Melanoma × Other solid neoplasm × Clear all

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

NCT05047536 2025-12-19

KZR-261 in Subjects With Advanced Solid Malignancies

Phase 1 Terminated

61 enrolled 25 charts

DermatologicGastrointestinalOther solid neoplasmThoracic

Uveal Melanoma, Melanoma, Mesothelioma, Neoplasm Metastasis, Colorectal Neoplasms

NCT03652077 2021-11-15

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Phase 1 Completed

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Clinical Trials

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

KZR-261 in Subjects With Advanced Solid Malignancies

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies